|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:MAP7-ARG1 (FusionGDB2 ID:51207) |
Fusion Gene Summary for MAP7-ARG1 |
Fusion gene summary |
Fusion gene information | Fusion gene name: MAP7-ARG1 | Fusion gene ID: 51207 | Hgene | Tgene | Gene symbol | MAP7 | ARG1 | Gene ID | 9053 | 64129 |
Gene name | microtubule associated protein 7 | tubulointerstitial nephritis antigen like 1 | |
Synonyms | E-MAP-115|EMAP115 | ARG1|LCN7|LIECG3|TINAGRP | |
Cytomap | 6q23.3 | 1p35.2 | |
Type of gene | protein-coding | protein-coding | |
Description | ensconsinMAP-7dJ325F22.2 (microtubule-associated protein 7 (EMAP115, E-MAP-115))epithelial microtubule-associated protein of 115 kDa | tubulointerstitial nephritis antigen-likeOLRG-2P3ECSLTIN Ag-related proteinTIN-Ag-RPTINAG-like 1androgen-regulated gene 1glucocorticoid-inducible protein 5lipocalin 7oxidized-LDL responsive gene 2tubulointerstitial nephritis antigen-related prot | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | . | P05089 | |
Ensembl transtripts involved in fusion gene | ENST00000354570, ENST00000454590, ENST00000544465, ENST00000438100, ENST00000432797, | ENST00000368087, ENST00000356962, ENST00000498260, | |
Fusion gene scores | * DoF score | 15 X 11 X 9=1485 | 2 X 3 X 2=12 |
# samples | 18 | 2 | |
** MAII score | log2(18/1485*10)=-3.04439411935845 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(2/12*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
Context | PubMed: MAP7 [Title/Abstract] AND ARG1 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | MAP7(136871480)-ARG1(131904200), # samples:3 | ||
Anticipated loss of major functional domain due to fusion event. | MAP7-ARG1 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. MAP7-ARG1 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF. MAP7-ARG1 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF. MAP7-ARG1 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | ARG1 | GO:0006508 | proteolysis | 11170462 |
Fusion gene breakpoints across MAP7 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across ARG1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | BRCA | TCGA-B6-A0IQ-01A | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
ChimerDB4 | BRCA | TCGA-B6-A0IQ-01A | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
ChimerDB4 | BRCA | TCGA-B6-A0IQ-01A | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
Top |
Fusion Gene ORF analysis for MAP7-ARG1 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
Frame-shift | ENST00000354570 | ENST00000368087 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
Frame-shift | ENST00000354570 | ENST00000356962 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
5CDS-intron | ENST00000354570 | ENST00000498260 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-3CDS | ENST00000454590 | ENST00000368087 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-3CDS | ENST00000454590 | ENST00000356962 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-intron | ENST00000454590 | ENST00000498260 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-3CDS | ENST00000544465 | ENST00000368087 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-3CDS | ENST00000544465 | ENST00000356962 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-intron | ENST00000544465 | ENST00000498260 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-3CDS | ENST00000438100 | ENST00000368087 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-3CDS | ENST00000438100 | ENST00000356962 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-intron | ENST00000438100 | ENST00000498260 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-3CDS | ENST00000432797 | ENST00000368087 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-3CDS | ENST00000432797 | ENST00000356962 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
intron-intron | ENST00000432797 | ENST00000498260 | MAP7 | chr6 | 136871480 | - | ARG1 | chr6 | 131904200 | + |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for MAP7-ARG1 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for MAP7-ARG1 |
Go to FGviewer for the breakpoints of :-: - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
. | ARG1 |
FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathways critical for cell proliferation, respectively; the urea cycle takes place primarily in the liver and, to a lesser extent, in the kidneys. {ECO:0000305}.; FUNCTION: Functions in L-arginine homeostasis in nonhepatic tissues characterized by the competition between nitric oxide synthase (NOS) and arginase for the available intracellular substrate arginine. Arginine metabolism is a critical regulator of innate and adaptive immune responses. Involved in an antimicrobial effector pathway in polymorphonuclear granulocytes (PMN). Upon PMN cell death is liberated from the phagolysosome and depletes arginine in the microenvironment leading to suppressed T cell and natural killer (NK) cell proliferation and cytokine secretion (PubMed:15546957, PubMed:16709924, PubMed:19380772). In group 2 innate lymphoid cells (ILC2s) promotes acute type 2 inflammation in the lung and is involved in optimal ILC2 proliferation but not survival (By similarity). In humans, the immunological role in the monocytic/macrophage/dendritic cell (DC) lineage is unsure. {ECO:0000250|UniProtKB:Q61176, ECO:0000269|PubMed:15546957, ECO:0000269|PubMed:16709924, ECO:0000269|PubMed:19380772}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for MAP7-ARG1 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for MAP7-ARG1 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for MAP7-ARG1 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | ARG1 | P05089 | DB03904 | Urea | Small molecule | Approved|Investigational | |
Tgene | ARG1 | P05089 | DB00129 | Ornithine | Small molecule | Approved|Nutraceutical | |
Tgene | ARG1 | P05089 | DB06757 | Manganese | Small molecule | Approved|Nutraceutical |
Top |
Related Diseases for MAP7-ARG1 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | ARG1 | C0268548 | Hyperargininemia | 12 | CLINGEN;CTD_human;GENOMICS_ENGLAND;UNIPROT |
Tgene | ARG1 | C0004096 | Asthma | 2 | CTD_human |
Tgene | ARG1 | C0002514 | Amino Acid Metabolism, Inborn Errors | 1 | CTD_human |
Tgene | ARG1 | C0003949 | Asbestosis | 1 | CTD_human |
Tgene | ARG1 | C0018500 | Hair Diseases | 1 | CTD_human |
Tgene | ARG1 | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
Tgene | ARG1 | C0021053 | Immune System Diseases | 1 | CTD_human |
Tgene | ARG1 | C0023281 | Leishmaniasis | 1 | CTD_human |
Tgene | ARG1 | C0026848 | Myopathy | 1 | CTD_human |
Tgene | ARG1 | C0032927 | Precancerous Conditions | 1 | CTD_human |
Tgene | ARG1 | C0037116 | Silicosis | 1 | CTD_human |
Tgene | ARG1 | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
Tgene | ARG1 | C0282313 | Condition, Preneoplastic | 1 | CTD_human |
Tgene | ARG1 | C0750905 | Amino Acid Metabolism, Inherited Disorders | 1 | CTD_human |
Tgene | ARG1 | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
Tgene | ARG1 | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
Tgene | ARG1 | C2930617 | Pulmonary Fibrosis - from Asbestos Exposure | 1 | CTD_human |
Tgene | ARG1 | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
Tgene | ARG1 | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
Tgene | ARG1 | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |